The evolving role of rituximab in the treatment of pemphigus vulgaris: a comprehensive state-of-the-art review
- 3 April 2021
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 21 (4) , 443-454
Abstract
Introduction Pemphigus vulgaris (PV) is a life-threatening autoimmune mucocutaneous blistering disease. Systemic corticosteroids (CS), while life-saving, have several serious side effects. To improve treatment and prognosis, recently rituximab (RTX), a chimeric monoclonal antibody against CD20 molecule on B cells, has become popular. This Expert Opinion discusses clinical and scientifically relevant aspects of RTX treating PV. Area Covered This presentation describes the mechanism of action, clinical efficacy, safety, adverse events, protocols used, and clinical outcomes. Concerns for infection, reactivation of latent or previous infections, and high relapse rate are discussed. Expert opinion Use of RTX in PV is still a work in progress. There are many unanswered questions. FDA did not provide a protocol or guidelines. Whenever RTX is used, systemic corticosteroids are simultaneously used, albeit for a shorter duration and lower dose. Used in these doses for these durations they can cause immunosuppression. Would it be more appropriate if instead of 'First Line Therapy' it would be more advisable to use the term 'First Adjunctive Immunosuppressive Agent'?Keywords
Funding Information
- Dysimmune Disease Foundation
This publication has 84 references indexed in Scilit:
- Concurrent Cytomegalovirus and Herpes Simplex Virus Infection in Pemphigus Vulgaris Treated with Rituximab and PrednisoloneActa Dermato-Venereologica, 2013
- Rituximab in the Treatment of Pemphigus VulgarisDermatology and Therapy, 2012
- Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapyAnnals of the Rheumatic Diseases, 2012
- Immunosuppressive therapy for autoimmune bullous diseasesClinics in Dermatology, 2012
- Direct Effect of Rituximab in B-Cell–Derived Lymphoid Neoplasias: Mechanism, Regulation, and PerspectivesMolecular Cancer Research, 2011
- Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)Arthritis Research & Therapy, 2011
- A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceusJournal of the American Academy of Dermatology, 2011
- Rituximab Exerts a Dual Effect in Pemphigus VulgarisJournal of Investigative Dermatology, 2008
- Consensus statement on definitions of disease, end points, and therapeutic response for pemphigusJournal of the American Academy of Dermatology, 2008
- A Single Cycle of Rituximab for the Treatment of Severe PemphigusNew England Journal of Medicine, 2007